Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.

By E. Cohen, F. Rosen, W. Stadler, W. Recant, K. Stenson, D. Huo, E. Vokes. Journal of Clinical Oncology, 2003

612 citations recorded by the source corpus.

Subfields: Oncology, Otorhinolaryngology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/9a31b1d0a156c2be6b12a6cc847b628cb9c8966a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Jeremy N. Rich

Citations in the corpus

• Phase II trial of gefitinib in recurrent glioblastoma. (2004, background): “As in other cancer types, the expression of either EGFR form was neither associated with an increased sensitivity to gefitinib nor did the absence of EGFR expression or amplification preclude tumor control by gefitinib [12,28].”